Video: The MDR and IVDR Transitional Provision Extension: What EU Sponsors Must Understand for Compliance

NAMSA sits down with Adrian Keene, Vice President of Global Biological Safety/Validation and EMEA Consulting Services, to discuss the EU Parliament’s approval of the transitional provision extension of the EU MDR and IVDR. Provided is information on how the amendment, passed on 16 February 2023, outlines new compliance dates for legacy device and removes the sell-off period for both medical and IVD products.

Schedule a Consultation with NAMSA’s regulatory experts.

Let’s Talk About Your Project

Ask a question or request a meeting with a NAMSA expert to discuss your specific project. We will follow up as quickly as possible. Also, please tell us how you heard about NAMSA.

First Name*

Last Name/Surname*

Business Email*

Job Title*

Company*

Company Size*

Where Are You Based?*

Location of Company Office You Work At/Report To*

How can we help?

By choosing to submit your information to contact NAMSA, you are providing NAMSA consent to process and store your information on the NAMSA Network. At any time, you can submit a request to withdraw your consent for the use of information provided by you. For additional information, please visit our Privacy Policy.

Video: The MDR and IVDR Transitional Provision Extension: What EU Sponsors Must Understand for Compliance

Published:

Let’s Talk About Your Project